Search Bar & Filters
Found 140 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.
Actively Recruiting
Researchers are evaluating the safety and tolerability of Efimosfermin Alfa in adults with known or suspected metabolic dysfunction-associated steatohepatitis MASH at fibrosis stages F2 or F3. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how this drug affects participants with this liver condition. Participants will be randomly assigned to one of three groups receiving Efimosfermin Alfa at dose level 1, Efimosfermin Alfa at dose level 2, or a placebo. The treatment is administered as an injection, and the study will track effects and adverse events over 52 weeks. The study includes multiple assessments, including liver fibrosis measurements and blood tests to monitor liver health and other related factors. During the study, participants will undergo regular evaluations including blood tests, imaging scans, and clinical assessments up to Week 52 to monitor safety, liver function, and fibrosis changes. Researchers will measure treatment-emergent adverse events, laboratory abnormalities, and changes in liver fibrosis and fat content using various biomarkers and imaging techniques. This detailed monitoring helps assess the treatments impact and safety profile throughout the study period.
Actively Recruiting
Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.
Actively Recruiting
Researchers are evaluating ONM-501, a drug given as intratumoral injections, alone and in combination with cemiplimab, an immune checkpoint inhibitor, in patients with advanced solid tumors and lymphomas. This phase 1 study aims to find the maximum tolerated dose, minimum effective dose, and recommended dose for expansion of ONM-501. The study includes patients with various advanced cancers who have no alternative standard therapies available. The trial has three parts monotherapy dose escalation, combination therapy dose finding, and combination therapy dose expansion. ONM-501 is given once per week for three weeks followed by three weeks off, in 21-day cycles. Cemiplimab is given intravenously every three weeks during the combination phases. Dose escalation uses special methods to gradually increase doses, and after doses are established, patients will enroll in expansion cohorts for specific tumor types. Participants will have regular assessments including monitoring for side effects, blood tests to measure drug levels, and evaluation of tumor response over up to 24 months. Researchers will track treatment-emergent adverse events, dose-limiting toxicities, and serious adverse events. Outcomes such as objective response rate, duration of response, progression-free survival, and overall survival will also be recorded. The study involves close safety monitoring and follow-up throughout the treatment and observation periods.
Actively Recruiting
Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the WiSE CRT System combined with an intracardiac pacemaker to deliver completely leadless cardiac resynchronization therapy CRT for patients with heart failure. This study is a single-arm, prospective, multicenter, observational trial designed to assess this novel device system that provides left ventricular pacing along with right ventricular pacing for biventricular stimulation. Participants receive the WiSE CRT System implanted to provide left ventricular pacing in combination with an existing system that provides right ventricular pacing. Together, these devices deliver biventricular pacing to the heart. The study follows a single treatment group where WiSE System therapy is turned on alongside guideline-directed medical therapy. The trial collects data over a period that includes assessments at 1 month and 6 months after implantation. During the study, participants will be monitored for device and procedure-related complications, and evaluated with electrocardiograms to confirm biventricular capture at 1 and 6 months. Additional measures include changes in heart function such as ejection fraction and left ventricular volume, as well as improvements in heart failure symptoms and physical capacity using the New York Heart Association NYHA class and six-minute walk test at 6 months. The total participation duration extends up to 6 months, with safety and effectiveness closely observed throughout.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of IMP1734, a PARP1 selective inhibitor, in people with advanced solid tumors. This study includes patients with breast cancer, metastatic prostate cancer, ovarian cancer, and other solid tumors who have previously received certain treatments. The goal is to find an optimal dose for future clinical development by studying how the drug affects the body and how the body processes it. The study has two parts Part 1 involves gradually increasing doses of IMP1734 given as a daily oral tablet to identify the highest safe dose or maximum achievable dose. This includes testing the drug alone and in combination with other treatments for specific cancers like metastatic prostate, ovarian, and breast cancer. Part 2 focuses on refining the dose to find the best amount for future studies. Treatment can last up to three years after the first dose. Participants will be monitored closely with assessments of side effects, blood tests to study drug levels and effects, and evaluations of tumor response using standard criteria. Safety monitoring continues up to 30 days after the last dose. Researchers measure how well the drug is tolerated and its impact on the cancer over time. The total participation may extend up to three years, with ongoing evaluations during this period.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are studying the best steroid dose to treat acute T cell mediated rejection TCMR in people who have had kidney or kidney-pancreas transplants. TCMR is a type of rejection where the bodys immune system attacks the transplanted organ, which can cause serious complications or organ failure. This international, multi-center trial aims to find the lowest effective and safe steroid dose to manage this condition, addressing a long-standing question in transplant care. The trial compares four treatment approaches that differ in doses of intravenous methylprednisolone IV MP and oral prednisone taper. Participants receive either a high or low dose of IV MP for three days followed by a high or low dose of oral prednisone for seven days, then return to standard prednisone. This factorial design allows evaluation of both drugs dose effects. The study is sponsored by the University of Sydney and involves collaboration among several international transplant societies. Participants will be closely monitored with biopsies and blood tests to assess rejection resolution and kidney function over 12 weeks. Researchers will also track survival, kidney filtration rates, urine protein levels, infection rates, quality of life, and other health outcomes up to 48 weeks. The study includes regular visits and evaluations to ensure safety and collect data on treatment effects and side effects during the trial period.
1-10 of 140
1